Diabetes Drug Discovery & Research
Diabetes Research Tools

One true source for all your Diabetes related Peptides, Assay kits and Antibodies

AnaSpec boasts an essential collection of disease targeted drug discovery and research tools, including a portfolio specifically for diabetes and related metabolic disorders. By integrating our peptides, assay kits, dyes, proteins, and antibodies, into disease related groups, you get your research supplies from one source, which saves you time from searching multiple sites.
Diabetes is a growing epidemic whose prevalence is expected to increase from 415 million to 642 million worldwide by 20401. This chronic disease is associated with either insulin deficiency (type I) or insulin resistance (type II) presenting a strong case for pursuing and advancing research and development of projects/products targeting diabetes with a focus of promoting effective glucose tolerance.

Peptides

Features & Benefits
  • Consistently Recognized for our Quality Peptides
  • Manufactured by Our Highly Knowledgeable Scientists & Chemists
  • Purity ≥95%
  • Custom Synthesis Services Available
  • Peptide Potential Anti-Diabetic Roles
    Peptide Class Incretins, Glucagon like peptides & mimetics Somatostatins Pancreatic polypeptides IAP
    (Amylin)
    Exendins
    GLP-1
    GLP-1R
    agonists
    GIP GLP-2 SS-28 SS-14 PP
    PYY
    NPY
    Insulinotropic
    X
    X
     
     
     
     
     
     
    X
    Anorexigenic
    X
     
     
     
     
    X
    X
    X
     
    Suppress/inhibit glucagon secretion/ hepatic glucose production
    X
    X
     
    X
    X
     
     
    X
     
    Upregulates intestinal glucose transport/improves barrier function
     
    X
    Delays/inhibits gastric emptying
    X
    X
    X
    X
    X
    Promote pancreatic beta-cell growth, defferentiation, survival
    X
    X
    X
    X

    Peptide Case Study

     

    Incretin Peptides (GIP & GLP-1)

    Incretins stimulate insulin release but inhibit glucagon release resulting in lower blood sugar. Glucagon is a peptide hormone secreted from the pancreas in response to low circulating blood glucose levels in order to restore normal glucose levels.

    The incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gastro-intestinal derived hormones that are released following meal ingestion in an attempt to regulate postprandial secretion of insulin (insulinotropic incretin effect)4. These incretins have several actions by peripheral and central mechanisms including regulating appetite and body weight. Furthermore, targeting the incretin system appears to provide a basis for not only the understanding of its relation to obesity among diabetic patients but also as a therapeutic strategy for obesity and diabetes with promising benefits in addition to weight loss.

    Assay Kits (FRET & Fluorogenic)

    Features & Benefits
  • Optimized for Highly Sensitive Detection of Enzyme Activities
  • Compatible with HTS for Drug Discovery application
  • One-step Homogeneous Mix-and-Read Formats Available
  • Expert Assay Support (email or phone)
  • Custom Services Available
  • For technical & ordering Assay Kits information
      IDE
      Neprilysin
    Our line of diabetes related SensoLyte® Assay kits includes FRET or fluorogenic kits for the sensitive detection of protease activities.
    Inhibition of DPPIV activity measured with SensoLyte®Rh110 DPPIV Assay Kit
    DPPIV also known as CD26 is a widely distributed serine protease. It"s activity is critical for inactivation of GLP-1, a potent antihyperglycemic hormone, inducing glucose-dependent stimulation of insulin secretion. DPPIV inhibitors provide a potent treatment for type 2 diabetes prolonging the activity of GLP-1 and improving insulin secretion and blood glucose control regulation 2-3.The SensoLyte® Rh110 DPPIV Assay Kit provides a convenient method for high throughput screening of DPPIV inhibitors and for continuous assay of DPPIV activity utilizing a fluorogenic peptide. Upon enzyme cleavage, the peptide releases the Rh110 fluorophore with bright green fluorescence that can be detected at Ex/Em=490/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from reaction components.
    Assay Kit Case Study
    Inhibition of DPPIV activity measured with SensoLyte®Rh110 DPPIV Assay Kit.

    Antibodies

    Features & Benefits
  • Catalog & Custom Antibodies Available with Optimization
  • Optimized Antibody/Epitope Design & Production Available
  • Both Polyclonal (different hosts) & Monoclonal (from hybridomas) Production Available
  • Expert Antibody Support Available (email or phone)
  • For technical & ordering Antibodies information
    Anti - CTRP6 (CT)
      AS-54561
    Anti - Ghrelin - 28 (CT)
      AS-55068A
    Anti - Glucagon (IN - 1)
      AS-55154A
    Anti - Glucagon (IN - 2)
      AS-29667
    Our unique line of Antibodies including OptimAb™ antibodies results from leveraging expertise over 25 years in antibody production. We have acquired a strong expertise in developing both custom monoclonal and polyclonal antibodies against key protein targets in various hosts thereby advancing disease-centric research and drug development. 
    Featured Antibody
    Western blot analysis of recombinant human ghrelin protein (15 kDa) probed with anti-Ghrelin-28 (CT) antibody (Cat# AS-55068A)
    Ghrelin is an appetite stimulating peptide hormone secreted by the stomach of mammals, but is also detectable in many other tissues. Endogenous Ghrelin participates in the regulation of food intake, body weight and energy homeostasis.

    Anti-Ghrelin-28 (CT) rabbit polyclonal antibody (AS-55068A) was raised against KLH conjugated synthetic human Ghrelin-28 peptide and was validated for specificity by western blot. This antibody can be applicable for ELISA and western blot.

    References
    1.http://www.diabetesatlas.org/
    2.Zhu, L. et al, J. Biol. Chem 278, 22418 (2003).
    3.Mentlein, R. Regulatory Peptides 85, 9 (1998).
    4.Baggio LL, et al. Gastroenterology 132(6):2131-57 (2007).